is semaglutide compound the same as wegovy Compounded vs Diabetes advocacy group discourages use

Hypoglycaemia risk: Retatrutide, like other incretin-class agents, stimulates insulin secretion in a glucose-dependent manner, meaning the risk of hypoglycaemia with monotherapy in otherwise healthy individuals is generally low

Retatrutide activates three hormone pathways instead of one, which can lead to stronger appetite control and more significant weight-loss results

[1] [2] This gradual escalation is designed to minimise gastrointestinal side effects, which are common with this class of medicine

These results come from Phase 2 clinical trials published in NEJM (2023) and ongoing Phase 3 trials

Refills are done through the same workflow, with follow-up visits handled through the patient portal